David Alan Rizzieri, MD

Professor of Medicine
Member of the Duke Cancer Institute
Campus mail 1149 N Pavilion, Durham, NC 27710
Phone (919) 668-1040
Email address david.rizzieri@duke.edu

My research interests focus on the care of patients with hematologic malignancies, both with and without the use of bone marrow or stem cell transplantation. I focus my research efforts on new approaches to manipulate minimal residual disease.

Recent endeavors have included:

  1. Phase one trials with novel anti-cancer agents targeting aurora kinases, tyrosine kinases, mtor, VEGF, and raf/ras pathways 
  2. New monoclonal antibodies targeting tumor stroma rather than cellular antigens 
  3. Investigating new antibody targets, i.e. CD123, endoglin, or tenascin for hematologic malignancies 
  4. Aggressive therapy and transplantation for mantle cell lymphoma 
  5. Antiangiogenesis therapy for patients with NHL 
  6. Nonablative allogeneic transplantation therapy with matched or mismatched donors followed by immune modulation

Education and Training

  • Fellow in Hematology/Oncology, Medicine, Duke University, 1994 - 1997
  • Medical Resident, Medicine, Duke University, 1991 - 1994
  • M.D., University of Rochester, 1991


Kam, Angel Y. F., Sadhna O. Piryani, Chad M. McCall, Hee Su Park, David A. Rizzieri, and Phuong L. Doan. “Targeting High Mobility Group Box-1 (HMGB1) Promotes Cell Death in Myelodysplastic Syndrome..” Clin Cancer Res 25, no. 13 (July 1, 2019): 4155–67. https://doi.org/10.1158/1078-0432.CCR-18-3517.

Full Text

Rashidi, Armin, Mehdi Hamadani, Mei-Jie Zhang, Hai-Lin Wang, Hisham Abdel-Azim, Mahmoud Aljurf, Amer Assal, et al. “Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission..” Blood Adv 3, no. 12 (June 25, 2019): 1826–36. https://doi.org/10.1182/bloodadvances.2019000050.

Full Text

Lin, Kevin H., Abigail Xie, Justine C. Rutter, Yeong-Ran Ahn, Julia M. Lloyd-Cowden, Amanda G. Nichols, Ryan S. Soderquist, et al. “Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity..” Cell Metab 29, no. 5 (May 7, 2019): 1217-1231.e7. https://doi.org/10.1016/j.cmet.2019.01.011.

Full Text

Pemmaraju, Naveen, Andrew A. Lane, Kendra L. Sweet, Anthony S. Stein, Sumithira Vasu, William Blum, David A. Rizzieri, et al. “Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm..” N Engl J Med 380, no. 17 (April 25, 2019): 1628–37. https://doi.org/10.1056/NEJMoa1815105.

Full Text

Hudson, Kathryn E., David Rizzieri, Samantha M. Thomas, Thomas W. LeBlanc, Zachary Powell, Louis Diehl, Joseph O. Moore, Carlos DeCastro, and Anne W. Beaven. “Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study..” Br J Haematol 184, no. 4 (February 2019): 647–50. https://doi.org/10.1111/bjh.15138.

Full Text

Berdeja, J. G., M. C. Heinrich, S. R. Dakhil, S. L. Goldberg, M. Wadleigh, P. Kuriakose, J. Cortes, et al. “Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis.” Leukemia and Lymphoma, January 1, 2019. https://doi.org/10.1080/10428194.2019.1590569.

Full Text

Cook, Rachel J., Tamara Moyo, Jane L. Liesveld, David A. Rizzieri, Eytan M. Stein, Stephane De Botton, Gail J. Roboz, et al. “Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).” In Blood, Vol. 132. AMER SOC HEMATOLOGY, 2018. https://doi.org/10.1182/blood-2018-99-111285.

Full Text

Atallah, Ehab L., Johnnie J. Orozco, Michael Craig, Moshe Yair Levy, Laura E. Finn, Sharif S. Khan, Alexander E. Perl, et al. “A Phase 2 Study of Actinium-225 (Ac-225)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 mu ci/Kg/Dose.” In Blood, Vol. 132. AMER SOC HEMATOLOGY, 2018. https://doi.org/10.1182/blood-2018-99-111951.

Full Text

Jacobs, Kenneth, Cedric Viero, John Godwin, Jan Baughman, Jichao Sun, Kang Ying, John Muth, et al. “Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart (R) Molecule for T-Cell Redirected Therapy.” In Blood, Vol. 132. AMER SOC HEMATOLOGY, 2018. https://doi.org/10.1182/blood-2018-99-112615.

Full Text

Ying, Zhitao, Li Long, Hong Liu, Yuqin Song, David A. Rizzieri, Bijan Nejadnik, Jun Zhu, and Cheng Liu. “ET190L1-Artemis (TM) Cell Therapy Results in Durable Disease Remissions with No Cytokine Release Syndrome or Neurotoxicity in Patients with Relapsed and Refractory B-Cell Lymphoma.” In Blood, Vol. 132. AMER SOC HEMATOLOGY, 2018. https://doi.org/10.1182/blood-2018-99-113163.

Full Text